公开(公告)号：US20210353751A1

公开(公告)日：2021-11-18

申请号：US17286030

申请日：2019-10-18

申请人： The Regents of The University of California

发明人： Daniel Kaufman ,  Jide Tian

IPC分类号： A61K39/395 ,  A61K31/573 ,  A61K38/13 ,  A61K31/436 ,  A61K31/42 ,  A61K31/5377 ,  A61K31/407 ,  A61K31/519 ,  A61K31/5415 ,  A61K31/405 ,  A61K38/21 ,  A61K31/5513 ,  A61K31/515 ,  A61K31/145 ,  A61K31/197 ,  A61K31/351 ,  A61K31/401 ,  A61K31/05 ,  A61K31/437 ,  A61P3/10

摘要： The present application relates to a combination therapy for treatment of inflammatory diseases comprising an immunomodulator compound and a GABA-receptor agonist in an amount effective to reduce inflammation and ameliorate disease. In certain embodiments, the present application relates to treatment of T1D by administering an immunomodulator compound and a GABA-receptor agonist in an amount effective to prevent, reduce, and/or treat hyperglycemia in the human or animal subject. In certain embodiments, the immunomodulator compound and GABA-receptor agonist are administered in an amount effective to control autoimmune responses and safely increase β-cell mass and function in the context of established β-cell autoimmunity.

公开(公告)号：US11173115B2

公开(公告)日：2021-11-16

申请号：US17134827

申请日：2020-12-28

申请人： Pulmatrix Operating Company, Inc.

发明人： Jean C. Sung ,  Michael M. Lipp

IPC分类号： A61K9/00 ,  A61K47/02 ,  A61K47/18 ,  A61K31/439 ,  A61K31/58 ,  C07K16/00 ,  A61K31/137 ,  A61K31/407 ,  A61K31/4745 ,  A61K31/5383 ,  A61K31/56 ,  A61K38/00 ,  A61K38/28 ,  A61K39/00 ,  A61K31/496 ,  A61K31/7036 ,  A61K39/395

摘要： The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.

公开(公告)号：US20210346351A1

公开(公告)日：2021-11-11

申请号：US17212765

申请日：2021-03-25

申请人： Purdue Pharmaceutical Products L.P.

发明人： Thomas Jorg Mehrling ,  Enrique Maria Ocio

IPC分类号： A61K31/4184 ,  A61K38/06 ,  A61K31/407 ,  A61K31/427 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/58 ,  A61K31/69 ,  A61K38/05 ,  A61K31/502 ,  A61K31/55 ,  A61K39/395 ,  A61K45/06

摘要： The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.

公开(公告)号：US11154589B2

公开(公告)日：2021-10-26

申请号：US16343556

申请日：2017-11-02

申请人： The University of Melbourne

发明人： Greg GuangHua Qiao ,  Neil Martin O'Brien-Simpson ,  Shu Jie Lam ,  Eric Charles Reynolds

IPC分类号： A61K38/16 ,  A61P31/04 ,  A61K38/12 ,  A61K38/14 ,  A61K38/02 ,  A61K31/7056 ,  A61K31/635 ,  A61K31/43 ,  A61K31/7052 ,  A61K31/437 ,  A61K31/422 ,  A61K31/546 ,  A61K31/496 ,  A61K31/7048 ,  A61K31/7036 ,  A61K31/4375 ,  A61K31/407 ,  A61K31/65

摘要： This invention relates to compositions including antibacterial compounds. The invention also relates to the use of the compositions in methods of treating bacterial infections. In one aspect the present invention also provides a method of increasing the susceptibility of bacteria to the anti-bacterial activity of a compound, the method comprising contacting the bacteria with a star shaped peptide polymer of the invention, thereby increasing the susceptibility of the bacteria to the anti-bacterial activity of the compound. Preferably, the method further includes the step of contacting the bacteria with the compound for which the bacteria have increased susceptibility to. The invention is further relates to the combination of a star shaped peptide polymer and an anti-bacterial compound that restore the sensitivity of antibiotic resistant bacteria to antibiotics that are otherwise ineffective when administered alone.

公开(公告)号：US11154545B2

公开(公告)日：2021-10-26

申请号：US17244065

申请日：2021-04-29

申请人： Bow River LLC

发明人： Sundar Srinivasan ,  Christina Chow

IPC分类号： A61K31/496 ,  A61P35/00 ,  A61K31/4468 ,  A61P25/16 ,  A61K31/454 ,  A61K31/519 ,  A61K31/4745 ,  A61K31/397 ,  A61K31/498 ,  A61K31/497 ,  A61K31/5395 ,  A61K31/506 ,  A61K31/407 ,  A61P35/02 ,  A61P35/04 ,  A61K9/00 ,  A61K9/08 ,  A61K31/5383 ,  A61P25/18 ,  A61K31/4995 ,  A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K9/10

摘要： The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

公开(公告)号：US11136332B2

公开(公告)日：2021-10-05

申请号：US16886301

申请日：2020-05-28

申请人： Celgene International II Sàrl

发明人： Robert Mansfield

IPC分类号： A61K31/407 ,  A61P35/00 ,  C07D491/02 ,  C07D491/048

摘要： The present invention relates to polymorphic forms of marizomib (e.g., Morphic Form I). The morphic forms can be used alone and in pharmaceutical compositions for the treatment of disease.

公开(公告)号：US20210299070A1

公开(公告)日：2021-09-30

申请号：US17278051

申请日：2019-09-20

申请人： Jnana Therapeutics, Inc.

发明人： Giovanni Muncipinto ,  Lyn H. Jones ,  Terry J. Rettenmaier

IPC分类号： A61K31/166 ,  A61K31/277 ,  A61K31/4402 ,  A61K31/455 ,  A61K31/513 ,  A61K31/337 ,  A61K31/341 ,  A61K31/4409 ,  A61K31/44 ,  A61K31/4168 ,  A61K31/505 ,  A61K31/444 ,  A61K31/407 ,  A61K31/396 ,  A61K31/421 ,  A61K31/36 ,  A61K31/4439 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/4178 ,  A61K31/4164 ,  A61K31/4709 ,  A61K31/47 ,  A61K31/397 ,  A61K31/497

摘要： Disclosed are methods of treating creatine transporter deficiency, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that increases transport of a substrate by a mutant or wild-type creatine transporter. Also disclosed are methods of increasing transport of guanidinoacetic acid or a salt thereof across the blood-brain barrier of a mammal, and methods of decreasing accumulation or the concentration of guanidinoacetic acid or a salt thereof in a mammalian cell.

公开(公告)号：US20210290629A1

公开(公告)日：2021-09-23

申请号：US17226157

申请日：2021-04-09

申请人： Forschungzentrum Borstel Leibniz-Zentrum fuer Medizin und Biowissenschaften

发明人： Norbert REILING ,  Julius BRANDENBURG

IPC分类号： A61K31/5377 ,  A61K31/496 ,  A61K31/7036 ,  A61K31/438 ,  A61K31/4709 ,  A61K31/5383 ,  A61K31/43 ,  A61K31/407 ,  A61K31/7048 ,  A61K31/606 ,  A61K31/44 ,  A61K31/427 ,  A61K31/4965 ,  A61K31/4409 ,  A61K31/133 ,  A61P31/06

摘要： Compounds which are suitable for treating mycobacterial diseases and pharmaceutical compositions containing such compounds are provided. Also encompassed are such compounds for use in medicine. The disclosure further relates to a kit of parts comprising a pharmaceutical composition containing such compounds and at least one additional pharmaceutically active compound.

公开(公告)号：US20210283119A1

公开(公告)日：2021-09-16

申请号：US17332600

申请日：2021-05-27

申请人： Bow River LLC

发明人： Sundar SRINIVASAN ,  Christina CHOW

IPC分类号： A61K31/4468 ,  A61P25/16 ,  A61K31/454 ,  A61K31/519 ,  A61K31/4745 ,  A61K31/397 ,  A61K31/498 ,  A61K31/497 ,  A61K31/5395 ,  A61K31/506 ,  A61K31/407 ,  A61P35/02 ,  A61P35/04 ,  A61K9/00 ,  A61K9/08 ,  A61K31/5383 ,  A61P25/18 ,  A61K31/4995 ,  A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K9/10

摘要： The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

公开(公告)号：US20210283104A1

公开(公告)日：2021-09-16

申请号：US17337952

申请日：2021-06-03

申请人： Presage Biosciences, Inc.

发明人： Richard KLINGHOFFER ,  Joyoti DEY

IPC分类号： A61K31/4025 ,  A61K31/453 ,  A61K31/635 ,  A61K45/06 ,  A61K31/407 ,  A61K31/7072 ,  A61K31/519 ,  A61K31/69 ,  A61P35/02 ,  A61K9/00 ,  A61K47/06

摘要： The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by
Formula (I): or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.